The mechanism of heparin-induced platelet aggregation.
When heparin was added to platelet-rich plasma, mild but irreversible platelet aggregation was demonstrated. This platelet response was not accompanied by release of alpha-granules and dense body constituents, nor by prostaglandin biosynthesis. It did, however, require metabolic energy and divalent cations as metabolic inhibitors (anti-mycin A and 6-deoxyglucose) and EDTA blocked the reaction. Bernard-Soulier syndrome platelets, which lack glycoprotein (GP) Ib, but not Glanzmann's Thrombasthenia platelets, which lack GP IIb/IIIa, were aggregated by heparin. Monoclonal antibody (mAb) against GP IIb/IIIa, but not mAb against GP Ib, strongly inhibited the reaction. These combined results suggest the participation of GP IIb/IIIa but not GP Ib in heparin-induced platelet aggregation. Fibrinogen was a cofactor in the reaction as gel-filtered platelets were unreactive to heparin but addition of fibrinogen restored their reactivity. Antithrombin III and fibronectin inhibited platelet response to heparin, suggesting that these proteins may protect platelets from aggregation by heparin.
Chong
B H
BH
Department of Haematology, St. George Hospital, Kogarah, N.S.W., Australia.
Ismail
F
F
D000911:Antibodies, Monoclonal / Q000276:immunology; D000990:Antithrombin III / Q000494:pharmacology; D001790:Blood Physiological Phenomena; D001792:Blood Platelets / Q000378:metabolism; D005353:Fibronectins / Q000494:pharmacology; D006493:Heparin / Q000494:pharmacology*; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects*; D010980:Platelet Membrane Glycoproteins / Q000276:immunology; D012701:Serotonin / Q000378:metabolism; D013929:Thromboxane B2 / Q000096:biosynthesis
D000911:Antibodies, Monoclonal; D005353:Fibronectins; D010980:Platelet Membrane Glycoproteins; D012701:Serotonin; D013929:Thromboxane B2; D000990:Antithrombin III; D006493:Heparin